Outcomes Among Patients Receiving Watchman LAAO vs Antiplatelet Therapy
BACKGROUND: Although Watchman left atrial appendage occlusion (LAAO) was approved for patients with atrial fibrillation who can tolerate short term anticoagulation, many patients are poor candidates for any duration of anticoagulation. OBJECTIVES: The objective of the study was to compare 1-year outcomes among patients receiving Watchman LAAO vs antiplatelet monotherapy. METHODS: We performed an overlap weighted observational comparative effectiveness analysis of postdischarge outcomes among Medicare beneficiaries in the Get With The Guidelines-AFIB Registry who received LAAO or antiplatelet therapy. Cox Regression was used for all-cause mortality and cause-specific hazard models were used for nonfatal outcomes. A win ratio was calculated with the following endpoint hierarchy: 1) all-cause death; 2) stroke, systemic embolism, or transient ischemic attack (TIA); 3) major bleeding (excluding gastrointestinal bleeding); and 4) gastrointestinal bleeding. RESULTS: -VASC score 5). Through the first 45 days, the adjusted risk of stroke, TIA or systemic embolism, major bleeding, or death was lower among patients who received LAAO (HR: 0.26; CI: 0.17-0.41; P < 0.001). Between 46 days and 1 year, the risk for the composite outcome was lower among patients who received LAAO (HR: 0.61; CI: 0.48-0.78; P < 0.001). The win ratio at 1 year was 2.71 (95% CI: 1.92-3.83; P < 0.0001), indicating significantly better outcomes among LAAO patients. CONCLUSIONS: Among patients with atrial fibrillation, treatment with LAAO was associated with a lower risk of stroke, TIA or systemic embolism, major bleeding, or death compared to antiplatelet therapy.
Authors
- Daniel J. Friedman (ORCID: https://orcid.org/0000-0001-5791-1954)
- Iyanuoluwa Ayodele (ORCID: https://orcid.org/0000-0003-4480-1697)
- Brooke Alhanti (ORCID: https://orcid.org/0000-0003-4243-8062)
- Jonathan Paul Piccini (ORCID: https://orcid.org/0000-0003-0772-2404)
- José A. Joglar (ORCID: https://orcid.org/0000-0002-3267-7601)
- William R. Lewis (ORCID: https://orcid.org/0000-0002-6844-2505)
- Kenneth A. Ellenbogen (ORCID: https://orcid.org/0000-0002-8527-569X)
- Gregg C. Fonarow (ORCID: https://orcid.org/0000-0002-3192-8093)
- Anthony P. Kent
- KEVIN P. JACKSON (ORCID: https://orcid.org/0000-0002-2948-1333)
- Andrea M. Russo
- DaJuanicia Holmes
- Sreek Vemulapali
Institutions
- Medical University of South Carolina (US)
- Duke University (US)
- Virginia Commonwealth University (US)
- Ronald Reagan UCLA Medical Center (US)
- Cooper Medical School of Rowan University (US)
- Duke University Hospital (US)
- Duke Clinical Research Institute (US)
- Case Western Reserve University (US)
- Virginia Commonwealth University Medical Center (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- JACC Advances
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1016/j.jacadv.2026.103458
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Boston Scientific Corporation